Oxiracetam

Oxiracetam is a nootropic of the racetam class, a pyrrolidinone (2-oxo-pyrrolidine) derivative structurally related to piracetam. It has been studied for several decades as a cognition enhancer, with particular attention to memory, attention, and learning, and it is one of the racetams for which controlled human data exist. It is water-soluble and typically encountered in capsule or powder form.

The human literature is mixed but informative, which is a strength for an honest assessment. In a double-blind, placebo-controlled crossover study using the scopolamine model of amnesia in healthy volunteers, acute oral oxiracetam improved overall test performance, with a statistically significant benefit at 1600 mg on delayed recall of word lists and dose-related antagonism of scopolamine-induced deficits in semantic memory and attention ^[1]. By contrast, a double-blind, placebo-controlled trial in patients with probable Alzheimer's disease did not find improvement on a broad neuropsychological battery, indicating limited benefit in established dementia ^[2]. Reflecting continued clinical interest, a large multicenter Phase 3 randomized trial has been designed to test l-oxiracetam and oxiracetam for memory and cognitive impairment after traumatic brain injury ^[3].

Mechanistic and preclinical research has clarified how oxiracetam may support cognition and protect neural tissue. In a rat model of ischemic stroke, S-oxiracetam facilitated cognitive restoration by activating the alpha7 nicotinic acetylcholine receptor and the PI3K-mediated pathway, restoring synaptophysin function and increasing PSD-95 expression in the hippocampus ^[4]. Nanowired delivery of oxiracetam enhanced memory and functional recovery and induced neuroprotection after concussive head injury, reducing blood-brain barrier breakdown and edema ^[5].

Oxiracetam is used as a nootropic and research compound and is approved as a cognition-enhancing drug in some countries while remaining unapproved in others; its regulatory status varies by jurisdiction. Its combination of human and preclinical data, along with a generally favorable tolerability profile, keeps it among the more established racetams.

TOLERABILITY: consistently mild across five decades of trials. In the 289-patient dementia trial, 31 oxiracetam and 27 placebo patients reported minor unwanted effects, three withdrawals for poor tolerability in each arm, and no clinically or statistically significant routine laboratory changes (PMID 2693996). In a 65-patient trial, 4 oxiracetam patients reported 5 unwanted effects versus 1 placebo patient reporting 3; two oxiracetam patients were withdrawn for poor tolerability (PMID 1414239). Phase 1 oral: all AEs mild or moderate and dose-independent up to 2000 mg (PMID 37898393). Phase 1 intravenous: 1 mild possibly-related AE among 52 subjects, no serious AEs at up to 8 g (PMID 34549388). In the 590-patient phase 3 TBI trial the proportion of serious AEs did not differ between L-oxiracetam, oxiracetam and placebo (PMID 41381424). The class review concludes the racetams "possess a very low toxicity and lack serious side effects" (PMID 8061686), and a 194-trial network meta-analysis ranked oxiracetam among the five most favourable of 21 vascular-dementia drugs for adverse-reaction incidence (PMID 39239652).

ANIMAL TOXICOLOGY: in dogs, acute and 13-week repeated oral dosing produced loose stools as the main manifestation for both oxiracetam and S-oxiracetam; the proposed no-observed-adverse-effect level is 100 mg/kg (PMID 30351213).

RENAL CAUTION (pharmacokinetically grounded, not a documented adverse event): roughly 55 to 60% of an oral or intravenous dose is excreted unchanged in urine (PMIDs 37898393, 34549388). Clearance therefore depends on kidney function, and the dementia and stroke populations in which this drug is used are exactly the populations most likely to have reduced renal function. Dose reduction in renal impairment is a reasonable inference; no dedicated renal-impairment study was found.

DRUG INTERACTIONS: none characterised. No interaction study surfaced in this search, and the absence of measurable binding at CYP-relevant or receptor targets plus predominantly unchanged renal excretion makes major pharmacokinetic interactions unlikely on mechanistic grounds. This is an argument, not evidence; treat the interaction profile as unknown.

REGULATORY STATUS: - Italy: approved and marketed as Neuromet (400 mg and 800 mg tablets, SmithKline Beecham / GlaxoSmithKline S.p.A.), reportedly from 1984, for cognitive disorders of degenerative and multi-infarct dementia. Current AIFA marketing status could NOT be verified in this session. A 2010 review states flatly that "oxiracetam and aniracetam are no longer in clinical use" in the Western context (PMID 20166767). - China: approved and in active clinical use; registered preparations are 800 mg capsules and 1 g/5 mL injection. L-oxiracetam completed a phase 3 registration trial under China NMPA approval 2016L03521 (PMID 41381424). - South Korea: WITHDRAWN. The MFDS removed oxiracetam products after they failed clinical reassessment, and the government-commissioned 500-patient trial reports that its null result "support[s] the recent regulatory decision to suspend its use in South Korea" (PMID 41614470). This is the single most important regulatory fact and it is attested in the primary literature, not just press reporting. - United States: not FDA-approved for any indication, and not a lawful dietary-supplement ingredient. It is not a controlled substance; it circulates as a bulk "research chemical" powder with no manufacturing oversight, so identity and purity are not assured. - WADA: oxiracetam is NOT named on the Prohibited List. Phenylpiracetam (carphedon) is the only racetam named, under S6 stimulants, prohibited in-competition. The WADA S0 "non-approved substances" clause does not appear to reach oxiracetam because it holds real marketing approval in China. Verified against a secondary compilation of the WADA list only; the WADA PDF and GlobalDRO could not be fetched directly, so an athlete should confirm at GlobalDRO.com rather than rely on this line.

The documented interaction is with antiepileptic drugs, and it runs in one direction. In a pilot study in patients with epilepsy, concurrent carbamazepine or valproic acid shortened oxiracetam's half-life enough that the authors judged it would need more frequent dosing than usual to hold the same levels ^[31]. Both of those drugs affect hepatic clearance, so a nootropic being cleared faster alongside them is the expected direction.

The reverse did not happen: oxiracetam left serum concentrations of the antiepileptics themselves unchanged, and the authors concluded that long-term concurrent use is not contraindicated ^[31]. That is the reassuring half, and it is the half that matters more, since a compound that destabilised anticonvulsant levels would be a genuine hazard rather than an inconvenience.

This is one small pilot study from 1990, and it is close to the whole documented record for oxiracetam. Nothing here should be read as covering the stimulants or other nootropics it is usually stacked with; those pairings have not been studied.

Checking a whole stack? Run it through interactions + stacks.

Oxiracetam is a water-soluble pyrrolidinone nootropic developed by the Italian pharmaceutical company ISF in the late 1970s as a structural analog of piracetam, the parent racetam introduced earlier that decade. It was subsequently evaluated in clinical studies for dementia of the Alzheimer and multi-infarct types, as well as in models of stroke and traumatic brain injury. Human pharmacodynamic work in the early 1990s, including scopolamine-amnesia studies in healthy volunteers, helped establish its pro-cognitive credentials. It has been marketed in some countries as a cognitive aid while remaining a research compound in others.

Oxiracetam holds a favorable reputation as a clean, attention-forward racetam, with users reporting improved alertness, verbal fluency, and focus rather than sedation. It stands out for having one of the more substantial human evidence bases in its family, including a controlled study in which it counteracted scopolamine-induced amnesia and improved delayed recall. Mechanistic work points to the (S)-enantiomer acting through alpha-7 nicotinic receptors and PI3K/Akt signaling, with modulation of AMPA-receptor subunits. In fairness, a controlled trial in Alzheimer's disease found no significant benefit, suggesting its effects are clearest in acute, vascular, or injury-related contexts rather than advanced neurodegeneration.